12 Best Nasdaq Stocks Under $20 to Buy Now

6. Viatris Inc. (NASDAQ:VTRS)

Current market price: $8.98

Upside Potential: 17%

Number of Hedge Fund Holders: 48

Viatris Inc. (NASDAQ:VTRS) is a global pharmaceutical company focused on the development, manufacturing, and distribution of a broad portfolio of branded, generic, and over-the-counter medicines across multiple therapeutic categories.

For the fourth quarter of 2024, Viatris Inc. (NASDAQ:VTRS) reported revenue of $3.5 billion, reflecting a 1% increase on an adjusted basis. Full-year revenue grew by 2% to reach $14.7 billion, while adjusted earnings per share (EPS) came in at $2.65, marking an 8% decline year-over-year. Notably, the company generated $582 million in new product revenue during 2024, underscoring its ability to drive innovation. Additionally, Viatris successfully repaid $3.7 billion in debt over the fiscal year. However, in a setback, the company received a warning letter and import alert from the U.S. Food and Drug Administration (FDA) in December 2024 regarding its manufacturing facility in Indore, India. As a result, the company estimates a negative impact of approximately $500 million on total revenue for 2025 and a $385 million hit to adjusted EBITDA.

Following these developments, market sentiment has turned more cautious, reacting negatively to both the financial results and the FDA notice. Despite this, Jefferies analyst Glen Santangelo maintained a Buy rating on Viatris Inc. (NASDAQ:VTRS), though he revised his price target downward from $15 to $13. He acknowledged that while the company’s fundamentals continue to strengthen—anticipating 3% organic growth in FY25—its lowered EBITDA guidance has “overshadowed” the improvements in operational performance.